Pay in 4 interest-free payments of $42.50 Learn more
Ships within 48 hours · Estimated delivery Aug 11 - Aug 16
Combining P5091 with lenalidomide
as well as induces cell cycle arrest at the G2/M phase and apoptosis in
The cytotoxic effect of VPC-14337 on cardiac fibroblasts specifically under glucose- and glutamine-deficient condition
Smiles: CC1=CNC(C=C2C3=CC=CC=C3NC2=O)=C1CCC(O)=O
A-836339 60106 Combining P5091 with lenalidomideA 836339 is a drug developed by Abbott Laboratories that acts as a potent cannabinoid receptor full agonist. It is selective for CB2, with Ki values of 0. 64 nM at CB2 vs 270 nM at the psychoactive CB1 receptor, but while it exhibits selective analgesic, anti inflammatory and anti hyperalgesic effects at low doses, its high efficacy at both targets results in typical cannabis like effects appearing at higher doses, despite its low binding affinity for
US$ 20.00
US$ 24.00
US$ 15.00
US$ 33.00
US$ 16.00
US$ 10.00
US$ 14.00
US$ 18.00